Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Women's Health: Breaking the Incontinence Barrier

Executive Summary

Urinary incontinence is a growing health problem with increasing social and economic significance--the direct and indirect costs of treating it total almost $20 billion in the US alone. Device companies are providing a variety of treatment options for patients with UI, including a growing number of increasingly less invasive surgical options.

You may also be interested in...



Urinary Incontinence: Mesh Slings Come Under Fire

A large, undertreated patient population makes the urinary incontinence market an attractive arena for manufacturers; however, looming changes to the product approval process have added a level of uncertainty about future market growth.

Emerging Competitors in the SUI Market

The sheer size of the stress urinary incontinence market and the potential for future growth have attracted the attention of a number of emerging companies. Although investor interest has waxed and waned over the years, it appears to be heating up once again. This renewed interest is being driven in part by the push to develop efffective nonsurgical treatments that will appeal to an increasingly health-savvy patient population.

Prostate Cancer Market: $2 Billion and Growing

Although prostate problems have plagued men for many years, the growing elderly population is now driving an unprecedented increase in caseloads and a corresponding need for improved treatments. One of the primary concerns is the rise in prostate cancer diagnoses. With more than two million American men currently living with prostate cancer and more than 200,000 new cases diagnosed each year, the market for diagnostic and therapeutic products to address this disease is substantial; more than $2 billion in the US in 2007.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035217

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel